for the p53 Special Issue
1098-1004/asset/HUMU_left.gif?v=1&s=4065e12063da1c0efe3c1a74d4f13c3cd92fba18)
1098-1004/asset/HUMU_right.gif?v=1&s=58026811b6aa5bee5a3d0e0563a705f8b681f34d)
p53 Review Article
You have free access to this content
TP53 and ovarian cancer†
Article first published online: 24 FEB 2003
DOI: 10.1002/humu.10181
© 2003 Wiley-Liss, Inc.
Issue
1098-1004/asset/cover.gif?v=1&s=b02ab57a64d28403f477b09d50f72a4d63f4c8eb "Human Mutation")
Human Mutation
Special Issue: Focus on p53 and Cancer
Volume 21, Issue 3, pages 285–291, March 2003
Additional Information
How to Cite
Schuijer, M. and Berns, E. M.J.J. (2003), TP53 and ovarian cancer. Hum. Mutat., 21: 285–291. doi: 10.1002/humu.10181
- †
Publication History
- Issue published online: 24 FEB 2003
- Article first published online: 24 FEB 2003
REFERENCES
- , . 1993. Genetic epidemiology of epithelial ovarian cancer. Cancer 71:566–572.Direct Link:
- , , . 1999. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer. Ann Oncol 10:1335–1341.
- , , , , , , , . 1994. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 52:232–236.
- , , . 1998. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4:2433–2437.
- , . 2003. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176–181.Direct Link:
- , , . 1999. Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res 59:4973–4983.
- , , , , , . 2002. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 8:1196–1202.
- , . 1998. Ovarian cancer in infertility patients. Ann Med 30:525–528.
- , , . 1999. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 23:323–328.
- . 1993. Cancer of the ovary. N Engl J Med 329:1550–1559.
- , , . 1995. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The breast cancer linkage consortium. Genes Chromosomes Cancer 13:203–210.Direct Link:
- , , . 2000. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 53:367–375.
- , , , , . 1997. p53 mutations in BRCA1-associated familial breast cancer. Lancet 350:638–639.
- , , . 1995. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet 56:265–271.
- , , . 1992. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65:40–44.
- , , . 1997. p53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol 65:218–224.
- , , . 1991. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139:777–785.
- . 1971. Incessant ovulation: a factor in ovarian neoplasia? Lancet 2:163.
- . 1972. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv 27:751–768.
- , , . 1996. Increased sensitivity to cisplatin by nm23-transfected tumor cell lines. Cancer Res 56:2931–2935.
- FIGO (International Federation of Gynecology and Obstetrics). 1971. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 50:1–7.
- , , . 1993. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 54:220–225.Direct Link:
- , , . 1991a. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 49:57–60.Direct Link:
- , , . 1991b. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 49:61–65.Direct Link:
- . 1998. Prognostic factors in ovarian cancer. Semin Oncol 25:305–314.
- , , . 1998. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92:472–479.
- , , . 1994. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet 55:666–677.
- , , . 1996. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85:1009–1023.
- , , . 1994. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54:33–35.
- , , . 1993. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 53:1218–1221.
- , . 1997. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386:761, 763
- , , . 1994. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 102:671–676.
- , , . 1995. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 26:387–392.
- . 1992. Cancer. p53, guardian of the genome. Nature 358:15–16.
- , , . 1995. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 85:43–50.
- , , . 1995. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175–180.
- , , . 1995. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9:439–443.
- , , . 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71.
- , , . 1993. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53:1489–1492.
- , , . 1991. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 49:50–56.Direct Link:
- , , . 1998. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95:2302–2306.
- , , . 1992. Epithelial ovarian cancer. In: HoskinsWJ, PerezCA, YoungRC, editors. Principles and practice of gynecologic oncology. Philadelphia: JB Lippincott. p 731–781.
- , , . 1996. Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas. Br J Cancer 74:1592–1597.
- , , . 1993. Allelic loss on chromosome 17 in human ovarian cancer. Int J Cancer 54:85–91.Direct Link:
- , , . 1996. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 56:606–611.
- , , . 1995a. Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 26:393–397.
- , , . 1995b. Hypermethylation at a chromosome 17 “hot spot” is a common event in ovarian cancer. Hum Pathol 26:398–401.
- , , . 1999. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma. Hum Pathol 30:203–207.
- , . 1991. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12:14–26.
- , , , , , , , , , . 1999. Increased frequency pf TP53 mutations in BRCA1 and BRCA2 ovarian tumors. Genes Chromosomes Cancer 25:91–96Direct Link:
- , , , , , , , , , , . 2002. Immunochemical analyses of sporadic and familial ovarian cancer in Israel. Eur J Cancer 36:1120–1124.
- , , , , , , , . 1998. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 58:3193–3196.
- . 1996. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 63:254–257.
- . 1998. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774–1786.
- , . 1999. Complexity of surveillance for cancer risk associated with in-vitro fertilisation. Lancet 354:1573–1574.
- , , . 1997 Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 80:1241–1249.Direct Link:
- , , , , , , . 1998. p53 mutations in BRCA1-associated familial breast cancer. Lancet 352, 622
- , . 1999. Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol Cell Endocrinol 155:143–152.
- , , . 1996. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 56:1997–2002.
- , , , , , , , , , . 1999. Genetic alterations in ovarian borderline tumours and ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol 82:147–150.
- , , . 2001. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: A multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85:1359–1367.
- . 1977. Ovarian tumours: a review. Am J Pathol 87:686–720.
- , , . 1973. International histological classification and staging of tumors, histologic typing of ovarian tumors. Geneva: World Health Organization.
- , , . 1995. The genetic analysis of ovarian cancer. Br J Cancer 72:521–527.
- , , . 1996. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 13:117–123.
- , , . 1997. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 181:158–165.Direct Link:
- , , . 1995. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 55:2998–3002.
- , , . 1996. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer. Oncogene 12:735–740.
- , , . 1993. Whole chromosome 17 loss in ovarian cancer. Genes Chromosomes Cancer 8:195–198.Direct Link:
- , , . 1993. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53:3103–3108.
- , , . 1999. BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization. Clin Chem 45:976–981.
- , , . 1995. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the european organization for research and treatment of cancer. N Engl J Med 332:629–634.
- , , , , , , , , , , . 2002. Phase I trial of intraperitoneal injection of the 1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 20:1562–1569.
- , , . 1995. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 346:995–1000.
- , , . 1999. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354:1586–1590.
- . 1997. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 90:641–642.
- , , . 1994. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 86:1549–1551.
- , , . 1996. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors. Oncogene 12:2147–2153.
- . 1976. History of ovarian neplasia: facts and fancy. Obstet Gynecol Annual 5:331–344.
- , , . 1990. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021–1027.
- , , . 1998. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713–1721.